Zhongjing Vision Secures Tens of Millions in Pre-A Funding, Setting a New Benchmark in Eye Health Consumer Innovation

Nthoptic, a broad vision illuminated.

VCBeat learned第一时间 that Nthoptic is committed to "ushering in a new era of human visual science with cutting-edge technology."Nthoptic (Suzhou) Optical Technology Co., Ltd. (hereinafter referred to as "Nthoptic")Following the successful acquisition of angel round investment in 2023, a Pre-A round financing of tens of millions of yuan was successfully completed recently, led byRuihua CapitalLead investor,TigerYeah Capital, Borchid CapitalCo-investment,G&G CapitalActing as the exclusive financial advisor for the long term, this round of financing will help Nthoptic to further advance clinical research, market promotion, brand building, and new technology development. It will also support the creation of more innovative eye health products, effectively addressing unmet needs and pain points in clinical settings, and leading a new trend in eye health consumption.

Myopia has become a highly prevalent disease worldwide. According to statistics from international authoritative institutions, it is estimated that by 2050, the number of people with myopia globally will reach 5 billion. The myopia rate among Chinese teenagers consistently ranks first in the world. With the high attention given to myopia prevention and control for teenagers through national policies, continuous consumption in myopia prevention and control has formed a long-term growth trend, which is bound to grow into a trillion-yuan-scale industry.

The core mechanism of existing myopia prevention and control products is to create static optical signal stimulation in the peripheral retinal area ("peripheral defocus") through refractive means. However, a constant optical signal sequence can easily lead to neural adaptation in the optic nerve, causing the effectiveness of myopia prevention and control to saturate over time ("static defocus saturation"). Based on the innovative spatiotemporal optical phase technology theory, Nthoptic has launched the only innovative product category in the market — STOP KIT™ Dynamic Spatiotemporal Optical Film, effectively solving the problem of static defocus saturation.

STOP KIT™ Dynamic Spatiotemporal Optical Film is the first innovative product of Nthoptic. The company has successfully developed composite new materials, combined with globally patented microstructure design and light engraving technology, to take the lead in realizing its medical clinical application, providing a long-term and comprehensive solution for adolescent myopia prevention and control.

STOP KIT™ delivers comfortable visual quality and relies on lithography technology to form irregular water droplet-shaped microstructures with dynamic refractive power on the material's surface. This introduces optical indices of time, space, and phase, featuring toric, asymmetrical directional optical design. The product material can be widely applied to the front surface of optical lenses, preserving the original refractive effect of the lenses while generating comprehensive dynamic optical signal stimulation on the retina, thereby achieving long-lasting myopia control effects. Additionally, STOP KIT™ excels in patient compliance, visual quality, and ease of use, offering a comprehensive new experience for patients seeking myopia prevention and control.

As the end of June approaches, the global synchronized pre-launch of STOP KIT™ Dynamic Spatiotemporal Optical Film is about to be released. In order to create a medical product with strong consumer attributes and bring a brand-new user experience to teenagers with myopia and their parents, the company has developed a dedicated fitting device of strategic significance for the commercial promotion of the product. This device has the following four unique advantages:

• Build a Bridge of Trust Between Doctors and Patients

• Precision Medicine Channel Management

• Immediate fitting, ready to take away

• User Personalized Data Management

The company also actively responds to national strategic goals and expands product application scenarios, evolving from traditional "control" to the more cutting-edge "prevention" to meet the urgent needs of parents in protecting the hyperopia reserve of young children.

Nthoptic was founded in 2022. The founder and core team have深耕 (deeply engaged) in the ophthalmology field for twenty years, possessing extensive experience in clinical promotion and brand building. They have successfully commercialized multiple products in China's ophthalmology clinical field. Within just two years, they advanced the globally unique STOP KIT™ Dynamic Spatiotemporal Optical Membrane to the commercialization stage, fully demonstrating the founding team's exceptional technology transformation, commercialization capabilities, and pragmatic business philosophy.

In addition to the STOP KIT™ Spatiotemporal Optical Film product, the company has also developed a range of products including wearable devices for dry eye syndrome, digital optometry peripherals, and presbyopia correction. The scientist team leading the development is at the forefront of visual science research and has successfully developed several groundbreaking visual products that have been successfully commercialized. Building on this foundation, Nthoptic will continue to develop cutting-edge technologies and products in the field of ophthalmic consumer healthcare, meeting the eye health needs of users of all ages in their daily lives.

Nthoptic Founder Gu JiajiaFirst of all, I sincerely thank Ruihua Capital, TigerYeah Capital, Borchid Capital, and G&G Capital for their recognition and trust, which have injected strong momentum into our development. At the same time, I would like to express my heartfelt gratitude to Waterwood Ventures and Qingstone Capital from the angel round. Their continuous support and trust have enabled us to move forward steadily. This round of financing will further accelerate Nthoptic's development pace, allowing us to delve deeper into innovative technologies in the optometry industry and provide broader and more personalized vision science solutions to meet the growing needs of users, helping global users enjoy clearer and more convenient visual experiences.

Ruihua CapitalRepresentation: As China elevates the issue of myopia prevention and control among teenagers to the level of national policy, there is an urgent need for a long-term effective, visually superior, and highly safe solution for myopia control. Nthoptic, as an innovative pioneer in ophthalmic medical devices, meets this pressing demand with its cutting-edge R&D platform and breakthrough technology. Its globally pioneering exclusive S.T.O.P Spatiotemporal Optical Phase technology will usher myopia prevention and control into a new era. The founding team, led by Ms. Gu Jiajia, boasts over 20 years of experience in the ophthalmic medical device industry, with extensive expertise and resources accumulated in market promotion, sales strategy, and clinical applications, laying a solid foundation for the company's development. We believe that with its innovative technology, outstanding products, and experienced team, Nthoptic will shine brilliantly in the field of ophthalmic healthcare and make significant contributions to the cause of myopia prevention and control among teenagers.

Dr. Ji Tianrong from TigerYeah CapitalRepresentation: The overall myopia rate among children and adolescents in China exceeds 50%, becoming a social issue of significant concern for parents and the country. However, existing myopia control products on the market, such as orthokeratology lenses (OK lenses), static defocus spectacle lenses, and atropine eye drops, have various shortcomings, with limited long-term prevention and control effects. Clinical needs are far from being met. Nthoptic has adopted a new generation of dynamic spatiotemporal principles; its products balance myopia prevention and control effectiveness, visual quality, ease of use, and more. With over two decades of experience in the ophthalmology industry, the team is highly experienced. We look forward to the company quickly promoting its products to the market, benefiting myopic children and adolescents across China.

Borchid Capital, Shi LinglinMyopia prevention and control is a market with dual attributes of both healthcare and consumer goods. More than half of China's teenagers suffer from myopia. Beyond solutions like corrective surgeries and orthokeratology lenses (OK lenses), we have observed that defocus glasses, known for their convenience, safety, and effectiveness, have become a new choice for many consumers. We believe that Nthoptic’s unique dynamic product concept and design can provide consumers with an innovative and more effective solution. In the future, with the development and implementation of more groundbreaking vision products, Nthoptic will emerge as a new brand in the vision health consumer market. Borchid Capital will continue to support the long-term growth of companies in the health and technology consumption sectors.

Sun Xiaodan, Founder of G&G CapitalIt is a great honor to meet, serve, and accompany Ms. Gu and Nthoptic for the long term. The experience of working with Ms. Gu will become one of the most unforgettable memories in our careers. Her resilience, focus, diligence, proactive spirit, and keen business acumen have shown us what makes an outstanding founder. The Nthoptic team has deep technical expertise, profound insights into clinical and customer needs, and extensive experience in academic promotion and commercialization. Under the leadership of founder Ms. Gu, we firmly believe that the company will become a great enterprise in the field of eye health consumption.

Ruihua Capital's business scope covers investments in the stock circulation market, private equity,定向增发, private (trust) funds, and financial derivatives. Equity investment focuses on key areas such as healthcare, new energy, and semiconductors, adhering to Ruihua's core values of "purity, progress, win-win, long-term vision, and ethical practices," providing comprehensive value-added services to enterprises and becoming a long-term strategic partner.

TigerYeah Capital was established in 2014 as an independent venture capital firm under Tigermed. TigerYeah Capital focuses on equity investments in early and growth-stage healthcare sectors, with a management team that possesses deep industry backgrounds, extensive industry resources, and rich investment experience. To date, it has completed investments totaling 2 billion yuan across more than a hundred projects, with a portfolio covering medical devices, biopharmaceuticals, CROs, and health supplements. By empowering its invested companies, TigerYeah Capital creates value for the development of the healthcare industry in China and globally, contributing to public health.

Borchid Capital, founded in 2018, is a boutique venture capital firm focusing on early to mid-stage new consumer trends and the application of core TMT technologies. It is committed to investing in the vision of a better life, aiming to be a precise early value discoverer and a significant long-term companion for entrepreneurs. The core founders of Borchid Capital come from top-tier domestic and international venture capital firms, possessing over a decade of investment experience and having successfully invested in multiple listed companies both domestically and internationally.

G&G Capital, headquartered in Beijing, is a leading financial advisory firm in China that focuses on the healthcare industry. The core team members all have a background in the healthcare sector, with over a decade of experience in business development, corporate investment management, or entrepreneurship within their specialized fields. They possess an in-depth understanding of enterprise growth and industry dynamics, providing integrated financial-industrial support to outstanding pharmaceutical companies through their multidimensional knowledge structure and extensive network of contacts.